PMID- 37705602
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230916
IS  - 2214-6237 (Electronic)
IS  - 2214-6237 (Linking)
VI  - 33
DP  - 2023 Sep
TI  - Reproducibility of in-home CFRD screening using continuous glucose monitoring and 
      mixed meal tolerance test.
PG  - 100323
LID - 10.1016/j.jcte.2023.100323 [doi]
LID - 100323
AB  - BACKGROUND: Cystic fibrosis related diabetes (CFRD) is associated with 
      insulin-remediable pulmonary decline, so early detection is critical. Continuous 
      glucose monitors (CGM) have shown promise in screening but are not recommended by 
      clinical practice guidelines. Little is known about the reproducibility of CGM 
      results for a given patient. METHODS: Twenty non-insulin treated adults and 
      adolescents with CF placed an in-home CGM and wore it for two 14-day periods. 
      Participants underwent a mixed meal tolerance test (MMTT) on day 5 of each 14-day 
      period. Glycemic data from CGM 1 and CGM 2 were compared regarding published 
      thresholds to define abnormality: percent time >140 mg/dL of >/=4.5%, percent time 
      >140 mg/dL of >17.5%, and percent time >180 mg/dL of >3.4%. Results of the repeat 
      MMTT were compared for peak glucose and 2-hour glucose thresholds: >140 mg/dL, 
      >180 mg/dL, and >200 mg/dL. RESULTS: For percent time >140 mg/dL of >/= 4.5%, five 
      of 20 subjects had conflicting results between CGM 1 and CGM 2. For percent time 
      >140 mg/dL of >17.5% and >180 mg/dL of >3.4%, only one of 20 subjects had 
      conflicting results between CGM 1 and CGM 2. On the MMTT, few participants had a 
      2-hour glucose >140 mg/dL. Peak glucose >140 mg/dL, 180 mg/dL, and 200 mg/dL were 
      more common, with 10-37% of participants demonstrating disagreement between CGM 1 
      and CGM 2. CONCLUSIONS: Repeated in-home CGM acquisitions show reasonable 
      reproducibility regarding the more stringent thresholds for time >140 mg/dL and 
      >180 mg/dL. More data is needed to determine thresholds for abnormal mixed meal 
      tolerance tests in CFRD screening.
CI  - (c) 2023 The Authors. Published by Elsevier Inc.
FAU - Kutney, Katherine
AU  - Kutney K
AD  - Case Western Reserve University, Cleveland OH, United States.
AD  - University Hospitals Rainbow Babies and Children's Hospital, Cleveland OH, United 
      States.
FAU - Kaminski, Beth A
AU  - Kaminski BA
AD  - Case Western Reserve University, Cleveland OH, United States.
AD  - University Hospitals Rainbow Babies and Children's Hospital, Cleveland OH, United 
      States.
FAU - Casey, Terri
AU  - Casey T
AD  - Case Western Reserve University, Cleveland OH, United States.
AD  - University Hospitals Rainbow Babies and Children's Hospital, Cleveland OH, United 
      States.
FAU - O'Riordan, MaryAnn
AU  - O'Riordan M
AD  - Case Western Reserve University, Cleveland OH, United States.
AD  - University Hospitals Rainbow Babies and Children's Hospital, Cleveland OH, United 
      States.
FAU - Gubitosi-Klug, Rose
AU  - Gubitosi-Klug R
AD  - Case Western Reserve University, Cleveland OH, United States.
AD  - University Hospitals Rainbow Babies and Children's Hospital, Cleveland OH, United 
      States.
LA  - eng
PT  - Journal Article
DEP - 20230825
PL  - Netherlands
TA  - J Clin Transl Endocrinol
JT  - Journal of clinical & translational endocrinology
JID - 101629335
PMC - PMC10495624
OTO - NOTNLM
OT  - Continuous glucose monitor
OT  - Cystic Fibrosis Related Diabetes
OT  - Reproducibility
OT  - Screening
COIS- The authors declare the following financial interests/personal relationships 
      which may be considered as potential competing interests: Katherine Kutney 
      reports financial support was provided by Cystic Fibrosis Foundation.
EDAT- 2023/09/14 06:42
MHDA- 2023/09/14 06:43
PMCR- 2023/08/25
CRDT- 2023/09/14 04:01
PHST- 2023/06/02 00:00 [received]
PHST- 2023/07/23 00:00 [revised]
PHST- 2023/08/24 00:00 [accepted]
PHST- 2023/09/14 06:43 [medline]
PHST- 2023/09/14 06:42 [pubmed]
PHST- 2023/09/14 04:01 [entrez]
PHST- 2023/08/25 00:00 [pmc-release]
AID - S2214-6237(23)00011-X [pii]
AID - 100323 [pii]
AID - 10.1016/j.jcte.2023.100323 [doi]
PST - epublish
SO  - J Clin Transl Endocrinol. 2023 Aug 25;33:100323. doi: 10.1016/j.jcte.2023.100323. 
      eCollection 2023 Sep.